Navigation Links
A Blood Sample Predicts if Cancer Patients Respond to Therapy

STOCKHOLM, May 2, 2013 /PRNewswire/ --

Karolinska Institutet and University Hospital have shown that a simple blood test can predict breast cancer patients response to therapy, how long treatment will be effective and survival. The results are being presented at the IMPAKT scientific conference in Brussels, May 2-4. The analysis measures growth rate and this is the first time ever that one test have documented this by analysing a blood sample.

     (Photo: )

The study (called TEX) included 287 women with breast cancer who were treated with two different kinds of chemotherapy. The test, DiviTum™, analyses cell-division rate in blood taken from patients before treatment initiation. Regardless of therapy, DiviTum™ predicted which groups of patients who would respond to treatment or not. Patients with tumours that expressed a low DiviTum™-value lived significantly longer, 38 months, compared to 21 months for those with high values.

"By analysing the growth rate in a blood sample we can receive new, valuable clinical information on patient risk and ability to respond to treatment. With DiviTum™ there is an opportunity to identify patients who are at high risk for progression, and this group possibly requires more intense or different treatment", says Thomas Hatschek , lead investigator for the study and Associate Professor at Karolinska Institutet.

"We are keen to look at more possibilities to use DiviTum™ and we will test whether the technology also can be used initially, after starting therapy, to predict and monitor the effect of a chosen treatment. This would at an early stage be a tool to determine whether treatment is appropriate or not. The fact that it only takes a blood sample is an advantage because other methods require tumour tissue", says Thomas Hatschek .

 "We look forward to continued collaboration with Karolinska Institutet, contributing to improved diagnostics and monitoring of cancer patients. It's very positive that the information DiviTum™ provides can give a more comprehensive picture of the disease", says Anders Rylander , CEO Biovica.

Biovica is a bio-diagnostic company, founded in 2009 and ISO 13485 certified for Quality Management Systems. DiviTum™ is CE labelled and MPA registered.
See also

For more information:
Thomas Hatschek , Associate Professor at Radiumhemmet, Karolinska University Hospital & Karolinska Institutet, Department of Oncology-pathology.
Mobile phone: + 46-(0)709-24-43-41      

Anders Rylander , CEO Biovica.
Mobile phone: +46-(0)761-61-21-90    

SOURCE Biovica International AB
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. FindTheBest Helps Parents Find Cord Blood Banks
2. Cord Blood America Announces DTCC Removes "Chill" Imposed in December 2010
3. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
4. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
5. Study finds chronic abnormal brain blood flow in Gulf War veterans
6. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
7. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
8. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
9. NxStage Extends Agreement to Supply Streamline Bloodlines, MasterGuard and Buttonhole Needle Technology to B. Braun
10. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
11. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
Post Your Comments:
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)... 2 nouvelles études permettent d ... différences entre les souches bactériennes retrouvées dans la plaque ... humains . Ces recherches  ouvrent une nouvelle ... charge efficace de l,un des problèmes de santé ... .    --> 2 nouvelles études permettent d ...
(Date:11/25/2015)... ANGELES and HOLLISTON, Mass. ... Technology, Inc. (Nasdaq: HART ), a biotechnology company ... that CEO Jim McGorry will present at ... December 1, 2015 at 2:30 p.m. PT. The presentation ... below) for 30 days. Management will also be available ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
Breaking Biology Technology:
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):